Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Altimmune stock

ALT
US02155H2004
A2N5Z6

Price

6.93
Today +/-
-0.07
Today %
-1.01 %

Altimmune stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Altimmune stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Altimmune stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Altimmune stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Altimmune's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Altimmune Stock Price History

DateAltimmune Price
1/28/20256.93 undefined
1/27/20257.00 undefined
1/24/20256.98 undefined
1/23/20257.06 undefined
1/22/20256.94 undefined
1/21/20256.83 undefined
1/17/20256.86 undefined
1/16/20256.71 undefined
1/15/20256.58 undefined
1/14/20256.23 undefined
1/13/20256.87 undefined
1/10/20256.87 undefined
1/8/20257.45 undefined
1/7/20257.31 undefined
1/6/20257.25 undefined
1/3/20257.26 undefined
1/2/20257.11 undefined
12/31/20247.21 undefined

Altimmune Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Altimmune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Altimmune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Altimmune’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Altimmune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Altimmune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Altimmune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Altimmune’s growth potential.

Altimmune Revenue, EBIT and net profit per share

DateAltimmune RevenueAltimmune EBITAltimmune Net Income
2030e842.66 M undefined818.68 M undefined544.84 M undefined
2029e525.71 M undefined268.82 M undefined298.34 M undefined
2028e323.76 M undefined64.56 M undefined225.07 M undefined
2027e32.94 M undefined-201.88 M undefined-103.44 M undefined
2026e0 undefined-189.67 M undefined-121.69 M undefined
2025e0 undefined-135.66 M undefined-105.47 M undefined
2024e6,736.7 undefined-103.22 M undefined-96.51 M undefined
2023426,000 undefined-83.51 M undefined-88.45 M undefined
2022-70,000 undefined-87.74 M undefined-84.71 M undefined
20214.41 M undefined-85.54 M undefined-97.09 M undefined
20208.19 M undefined-54.8 M undefined-49.04 M undefined
20195.8 M undefined-20.46 M undefined-20.97 M undefined
201810.33 M undefined-17.89 M undefined-42.48 M undefined
201710.74 M undefined-16.13 M undefined-51.36 M undefined
20163.24 M undefined-11.09 M undefined-11.46 M undefined
201510.64 M undefined-800,000 undefined-3.44 M undefined
201410.19 M undefined-10.19 M undefined-9.96 M undefined
201317.91 M undefined-10.84 M undefined-11.72 M undefined
201225.18 M undefined-6.27 M undefined-4.92 M undefined
201124.27 M undefined-11.73 M undefined-3.8 M undefined
201020.99 M undefined-18.91 M undefined-34.85 M undefined
200927.55 M undefined-25.97 M undefined-32.28 M undefined
200832.91 M undefined-19.11 M undefined-36.42 M undefined
200714.64 M undefined-16.51 M undefined-17.72 M undefined
20061.66 M undefined-14.53 M undefined-21.72 M undefined
2005590,000 undefined330,000 undefined280,000 undefined

Altimmune Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
01143227202425171010310105840000032323525842
--1,300.00128.57-15.63-25.9320.004.17-32.00-41.18--70.00233.33--50.0060.00-50.00------909.3862.5460.38
-1,000.0071.4331.2537.0450.0041.6740.0058.82100.00100.00333.33100.00100.00200.00125.00250.00-----31.253.101.901.19
000000000010000000000000000
0-21-17-36-32-34-3-4-11-9-3-11-51-42-20-49-97-84-88-96-105-121-103225298544
---19.05111.76-11.116.25-91.1833.33175.00-18.18-66.67266.67363.64-17.65-52.38145.0097.96-13.404.769.099.3815.24-14.88-318.4532.4482.55
000.030.080.090.110.160.160.170.190.210.230.432.813.1225.6441.2846.9353.250000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Altimmune Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Altimmune is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
1.45.152.722.95.811.811.212.710.518.615.62.98.833.737.2215.9190.3184.9197.82
01.543.88.99.37.46.53.60.41.50.43.83.514.60.40.21.11
001.26.59.80000000.86.410.77.85.42.33.74
0000000000000000000
68.710.512.912.50.90.50.20.20.20.44.51.10.51.985.46.96
70.17.658.446.125.523.619.519.714.319.217.34.523.539.339.4230.2204.1192.8209.63
05.26.65.36.31.20.80.50.40.30.20.20.61.31.822.21.71.01
0000000000000000000
0000000000000000000
01.21.30.90.90000001538.713.912.712.812.412.40
0002.52.32.32.32.32.32.32.318.80000000
00.70.31.50.30.10.10.10.10.10.100.20.20.10.10.100
07.18.210.29.83.63.22.92.82.72.63439.515.414.614.914.714.11.01
70.114.766.656.335.327.222.722.617.121.919.938.56354.754245.1218.8206.9210.64
                                     
065.400000000009.3000000.01
55.80126.5142.4157200.8208.5210.5217.9238.8240.471121.7170.2187.9417.3497.3568.4665.43
300-69,900-87,400-123,800-155,000-189,900-193,700-198,600-210,300-220,300-223,700-31,300-77,700-116,900-137,400-186,400-293,200-377,900-466,331
13.60.11.50.41.21.31-0.2-0.2-0.20-7.6-4.6-5-5-5-5-5.2-5
0000000000000000000
69.7-4.440.6193.212.215.811.77.418.316.732.148.748.345.5225.9199.1185.3194.1
00.81.43.91.93.11.41.71.10.40.520.10.400.624.82.07
0.11.62.96.29.832.72.33.11.11.533.64.13.811.410.211.110.07
0.300.78.41.80.10.51.40.50.40.10000.106.11.20
011.8013.40001.31.1000.50000000
00440000.810.70000.100000
0.414.2935.913.56.24.67.56.82.62.15.53.74.63.91218.317.112.14
0016.70.917.4001.70.7000.50.60.500000
0000000000005.90.100000
02.40.40.61.38.82.31.92.31.110.241.44.67.21.54.64.4
02.417.11.518.78.82.33.631.110.710.524.67.21.54.64.4
0.416.626.137.432.2156.911.19.83.73.16.214.26.68.519.219.821.716.54
70.112.266.756.435.427.222.722.817.22219.838.362.954.954245.1218.9207210.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Altimmune provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Altimmune's financial health and stability.

Assets

Altimmune's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Altimmune must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Altimmune after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Altimmune's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
0-15-13-36-32-34-3-4-11-9-3-11-46-39-20-49-97-84-88
000001,0000000000000000
000000000000-2-600000
0001-5-1012001-861-4014-8
000231222-22321438291021241620
00001,00000000000000000
000001,0000000000000000
0-13-13-13-28-14-7-2-7-8-3-6-20-9-9-34-78-62-75
0000-100000000-100-1200
-680-12-10-7210000013-1-28-7287-7313
-680-12-9-63100000130-28-7199-7313
0000000000000000000
0118-400030-2002-100000
7500124215061805133412213655686
691161218215351604153212213655686
-5053-61200000000000000
0000000000000000000
1-235-20-17901-28-3-1922-2510674-7924
0.55-14.32-14.52-13.71-29.18-15.23-7.88-2.32-7.25-8.56-3.31-6.57-20.38-10.41-9.63-34.65-90.55-62.72-75.86
0000000000000000000

Altimmune stock margins

The Altimmune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Altimmune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Altimmune.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Altimmune's sales revenue. A higher gross margin percentage indicates that the Altimmune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Altimmune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Altimmune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Altimmune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Altimmune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Altimmune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Altimmune Margin History

Altimmune Gross marginAltimmune Profit marginAltimmune EBIT marginAltimmune Profit margin
2030e100.47 %97.15 %64.66 %
2029e100.47 %51.13 %56.75 %
2028e100.47 %19.94 %69.52 %
2027e100.47 %-612.95 %-314.06 %
2026e100.47 %0 %0 %
2025e100.47 %0 %0 %
2024e100.47 %-1.53 M %-1.43 M %
2023100.47 %-19,603.29 %-20,762.21 %
2022100.47 %125,342.86 %121,014.28 %
2021100.47 %-1,939.68 %-2,201.59 %
2020100.47 %-669.11 %-598.78 %
2019100.47 %-352.76 %-361.55 %
2018100.47 %-173.18 %-411.23 %
2017100.47 %-150.19 %-478.21 %
2016100.47 %-342.28 %-353.7 %
2015100.47 %-7.52 %-32.33 %
2014100.47 %-100 %-97.74 %
2013100.47 %-60.52 %-65.44 %
2012100.47 %-24.9 %-19.54 %
2011100.47 %-48.33 %-15.66 %
2010100.47 %-90.09 %-166.03 %
2009100.47 %-94.26 %-117.17 %
2008100.47 %-58.07 %-110.67 %
2007100.47 %-112.77 %-121.04 %
2006100.47 %-875.3 %-1,308.43 %
2005100.47 %55.93 %47.46 %

Altimmune Stock Sales Revenue, EBIT, Earnings per Share

The Altimmune earnings per share therefore indicates how much revenue Altimmune has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Altimmune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Altimmune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Altimmune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Altimmune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Altimmune Revenue, EBIT and net profit per share

DateAltimmune Sales per ShareAltimmune EBIT per shareAltimmune Earnings per Share
2030e11.85 undefined0 undefined7.66 undefined
2029e7.39 undefined0 undefined4.19 undefined
2028e4.55 undefined0 undefined3.16 undefined
2027e0.46 undefined0 undefined-1.45 undefined
2026e0 undefined0 undefined-1.71 undefined
2025e0 undefined0 undefined-1.48 undefined
2024e0 undefined0 undefined-1.36 undefined
20230.01 undefined-1.57 undefined-1.66 undefined
2022-0 undefined-1.87 undefined-1.81 undefined
20210.11 undefined-2.07 undefined-2.35 undefined
20200.32 undefined-2.14 undefined-1.91 undefined
20190.44 undefined-1.56 undefined-1.6 undefined
20183.69 undefined-6.39 undefined-15.17 undefined
201724.98 undefined-37.51 undefined-119.44 undefined
201614.09 undefined-48.22 undefined-49.83 undefined
201550.67 undefined-3.81 undefined-16.38 undefined
201453.63 undefined-53.63 undefined-52.42 undefined
2013105.35 undefined-63.76 undefined-68.94 undefined
2012157.38 undefined-39.19 undefined-30.75 undefined
2011151.69 undefined-73.31 undefined-23.75 undefined
2010190.82 undefined-171.91 undefined-316.82 undefined
2009306.11 undefined-288.56 undefined-358.67 undefined
2008411.38 undefined-238.88 undefined-455.25 undefined
2007488 undefined-550.33 undefined-590.67 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

Altimmune business model

Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.com.

Altimmune SWOT Analysis

Strengths

Altimmune Inc has a strong intellectual property portfolio, which includes patents and proprietary technologies that provide significant competitive advantage in the pharmaceutical industry.

The company's experienced management team and skilled workforce contribute to its expertise in vaccine development and immunotherapeutics.

Altimmune Inc has established partnerships with leading organizations and institutions, fostering collaboration and enhancing its research and development capabilities.

Weaknesses

Altimmune Inc relies heavily on a few key products, which increases its vulnerability to market fluctuations and regulatory challenges.

The company's limited financial resources may hinder its ability to invest in research and development, marketing, and expansion into new markets.

Altimmune Inc has a relatively small market share compared to some of its larger competitors, making it more difficult to penetrate established markets.

Opportunities

The growing demand for vaccines and immunotherapeutics presents significant opportunities for Altimmune Inc to expand its product portfolio and increase market share.

Advancements in technology and the increasing awareness of the importance of preventive healthcare create opportunities for the company to develop innovative solutions and gain a competitive edge.

Altimmune Inc can explore strategic partnerships and collaborations to access additional resources, expertise, and new markets.

Threats

The pharmaceutical industry is highly regulated, and changes in regulations and compliance requirements can pose challenges and increase costs for Altimmune Inc.

Intense competition from larger pharmaceutical companies with established brands and resources poses a threat to Altimmune Inc's market share and growth.

The ongoing COVID-19 pandemic has created a competitive landscape with increased focus on vaccine development, potentially increasing competition and reducing the market opportunities for Altimmune Inc.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Altimmune Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Altimmune historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Altimmune shares outstanding

The number of shares was Altimmune in 2024 — This indicates how many shares 53.247 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Altimmune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Altimmune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Altimmune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Altimmune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Altimmune stock splits

In Altimmune's history, there have been no stock splits.

Altimmune dividend history and estimates

In 2024, Altimmune paid a dividend amounting to 0 USD. Dividend means that Altimmune distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Altimmune provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Altimmune’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Altimmune's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Altimmune Dividend History

DateAltimmune Dividend
2017873 undefined

Altimmune dividend payout ratio

In 2024, Altimmune had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Altimmune distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Altimmune represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Altimmune could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Altimmune's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Altimmune Payout Ratio History

DateAltimmune Payout ratio
2030e0 %
2029e0 %
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
2017-730.91 %
20160 %
20150 %
20140 %
20130 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Altimmune.

Altimmune latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.36 -0.32  (10.46 %)2024 Q3
6/30/2024-0.34 -0.35  (-1.63 %)2024 Q2
3/31/2024-0.37 -0.34  (8.31 %)2024 Q1
12/31/2023-0.44 -0.33  (24.64 %)2023 Q4
9/30/2023-0.43 -0.39  (9.05 %)2023 Q3
6/30/2023-0.47 -0.32  (31.8 %)2023 Q2
3/31/2023-0.48 -0.4  (17.41 %)2023 Q1
12/31/2022-0.51 -0.43  (15.09 %)2022 Q4
9/30/2022-0.51 -0.48  (5.9 %)2022 Q3
6/30/2022-0.48 -0.42  (12.45 %)2022 Q2
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Altimmune stock

Eulerpool World ESG Rating (EESG©)

50/ 100

🌱 Environment

47

👫 Social

33

🏛️ Governance

70

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Altimmune shareholders

%
Name
Stocks
Change
Date
6.88122 % The Vanguard Group, Inc.4,893,9211,777,8866/30/2024
6.85452 % BlackRock Institutional Trust Company, N.A.4,874,9351,173,2216/30/2024
4.80009 % State Street Global Advisors (US)3,413,827-495,4599/30/2024
4.30629 % Columbia Threadneedle Investments (UK)3,062,6371,577,1236/30/2024
3.86670 % Tang Capital Management, LLC2,750,00006/30/2024
3.10799 % Susquehanna International Group, LLP2,210,4011,294,1476/30/2024
2.24102 % Geode Capital Management, L.L.C.1,593,810357,0126/30/2024
1.57695 % Knoll Capital Management, LLC1,121,524554,3056/30/2024
1.24617 % Capital Fund Management S.A.886,277886,2776/30/2024
1.07194 % D. E. Shaw & Co., L.P.762,362408,0126/30/2024
1
2
3
4
5
...
10

Altimmune Executives and Management Board

Dr. Vipin Garg

(66)
Altimmune President, Chief Executive Officer, Director (since 2018)
Compensation 2.88 M

Dr. M. Scott Harris

(69)
Altimmune Chief Medical Officer
Compensation 1.45 M

Dr. M. Scot Roberts

(64)
Altimmune Chief Scientific Officer
Compensation 1.41 M

Mr. Richard Eisenstadt

(64)
Altimmune Chief Financial Officer
Compensation 619,694

Dr. Mitchel Sayare

(75)
Altimmune Independent Chairman of the Board (since 2010)
Compensation 311,086
1
2
3

Most common questions regarding Altimmune

What values and corporate philosophy does Altimmune represent?

Altimmune Inc represents a core value of innovation and commitment to transformative medical solutions. With a strong corporate philosophy focused on advancing novel therapies, Altimmune Inc continuously strives to improve patient outcomes through groundbreaking immunotherapies. The company's dedication to scientific excellence and rigorous research enables the development of cutting-edge vaccine candidates, including intranasal vaccines to combat infectious diseases. Altimmune Inc's vision encompasses pioneering approaches in immunology and the goal of addressing unmet medical needs worldwide. By leveraging its expertise, Altimmune Inc remains at the forefront of medical advancements, exemplifying a steadfast commitment to improving global health.

In which countries and regions is Altimmune primarily present?

Altimmune Inc is primarily present in the United States.

What significant milestones has the company Altimmune achieved?

Altimmune Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include the successful completion of Phase 2 clinical trials for its lead product candidate, AdCOVID, a single-dose intranasal COVID-19 vaccine. The company has also demonstrated the effectiveness of NasoShield, a vaccine for anthrax, in preclinical studies. Altimmune Inc has further enhanced its portfolio by acquiring Spitfire Pharma, a biopharmaceutical company focused on liver diseases. Additionally, the company has established collaborations with leading organizations, including the University of Alabama and the National Institutes of Health, to advance its innovative pipeline. These milestones highlight Altimmune Inc's dedication to advancing novel therapies and its potential for future growth in the biopharmaceutical industry.

What is the history and background of the company Altimmune?

Altimmune Inc is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. Founded in 1997, Altimmune has a rich history of innovation in the field of immunology. The company specializes in the development of novel vaccines and immune-modulating therapies to combat infectious diseases. Altimmune's proprietary platform technologies enable the rapid design and development of next-generation immunotherapies. With a strong commitment to scientific research and development, Altimmune aims to transform the treatment landscape by addressing unmet medical needs. With its experienced team and extensive portfolio, Altimmune Inc is poised to make a significant impact on the global healthcare industry.

Who are the main competitors of Altimmune in the market?

The main competitors of Altimmune Inc in the market include companies such as Inovio Pharmaceuticals, VBI Vaccines, Novavax, and Moderna Inc.

In which industries is Altimmune primarily active?

Altimmune Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Altimmune?

Altimmune Inc is a biopharmaceutical company with a business model focused on developing and commercializing novel immunotherapeutic products. The company aims to address various diseases and medical conditions through innovative vaccine technologies and immune modulation platforms. Altimmune Inc is committed to advancing its proprietary pipeline, leveraging its expertise in immunology and vaccine development. With a strong emphasis on research and development, Altimmune Inc strives to bring novel treatments to market that can positively impact the lives of patients worldwide.

What is the P/E ratio of Altimmune 2025?

The Altimmune P/E ratio is -3.5.

What is the P/S ratio of Altimmune 2025?

The Altimmune P/S ratio is 0.

What is the Quality Investing of Altimmune?

The Quality Investing for Altimmune is 3/10.

What is the revenue of Altimmune 2025?

The revenue cannot currently be calculated for Altimmune.

How high is the profit of Altimmune 2025?

The expected Altimmune profit is -105.47 M USD.

What is the business model of Altimmune

The company Altimmune Inc. is a biopharmaceutical company specializing in the development of immunotherapies and vaccines for various diseases. Its business model is based on innovative research and development to meet the increasingly complex challenges of the medical industry. The company operates in three business areas - Immundevelopment, Vaxine, and Altimmune UK. Immundevelopment focuses on the research of immunotherapies and viral infections such as hepatitis B, HIV, and influenza. Vaxine develops vaccines against flu, anthrax, MERS, RSV, and COVID-19. Altimmune UK is increasingly focused on the field of neuroscience and oncology. Altimmune is divided into two pillars, immunotherapy and vaccine development. The two pillars work closely together to accelerate and improve the development of therapies and vaccines. In the immunotherapy pillar, treatments are being researched that stimulate the immune system to fight against various diseases. In the vaccine development, Altimmune produces vaccines that induce active immunization against certain diseases. One of Altimmune's most important products is NasoVAX, an intranasally administered flu vaccine. Compared to conventional injectable vaccines, NasoVAX offers faster action and does not require a nurse. NasoShield, an intranasally administered anthrax vaccine, is another well-known product from Altimmune. The company has also developed COVID-19 vaccine candidates that are now being tested in clinical trials. Altimmune aims to develop innovative solutions for serious diseases. The company has a strong commitment to research and development and is committed to continuing its successes in drug development. The company's mission is to ensure the creation of cost-effective solutions and improvement of outcomes for patients. Through the development of novel therapies and vaccines, Altimmune is repeatedly praised as one of the most promising companies in the industry. With a growing product range and a strong research and development department, the company is well-equipped to tackle important medical challenges of the future. In the future, it will be of great importance for Altimmune to continue developing innovative products that meet medical requirements. The industry will evolve through new scientific discoveries and the use of cutting-edge technologies, and Altimmune strives to play a leading role in this transformation.

What is the Altimmune dividend?

Altimmune pays a dividend of 0 USD distributed over payouts per year.

How often does Altimmune pay dividends?

The dividend cannot currently be calculated for Altimmune or the company does not pay out a dividend.

What is the Altimmune ISIN?

The ISIN of Altimmune is US02155H2004.

What is the Altimmune WKN?

The WKN of Altimmune is A2N5Z6.

What is the Altimmune ticker?

The ticker of Altimmune is ALT.

How much dividend does Altimmune pay?

Over the past 12 months, Altimmune paid a dividend of 873 USD . This corresponds to a dividend yield of about 12,597.4 %. For the coming 12 months, Altimmune is expected to pay a dividend of 0 USD.

What is the dividend yield of Altimmune?

The current dividend yield of Altimmune is 12,597.4 %.

When does Altimmune pay dividends?

Altimmune pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Altimmune?

Altimmune paid dividends every year for the past 0 years.

What is the dividend of Altimmune?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Altimmune located?

Altimmune is assigned to the 'Health' sector.

Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Altimmune from 2/3/2017 amounting to 2.91 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2017.

When did Altimmune pay the last dividend?

The last dividend was paid out on 2/3/2017.

What was the dividend of Altimmune in the year 2024?

In the year 2024, Altimmune distributed 0 USD as dividends.

In which currency does Altimmune pay out the dividend?

The dividends of Altimmune are distributed in USD.

All fundamentals about Altimmune

Our stock analysis for Altimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.